Accepted Manuscript

Promising effect of rapamycin on multiple sclerosis

Bahram Bagherpour, Mansour Salehi, Rasool Jafari, Akram Bagheri, Ali Kiani, Masoud Edalati, Mohammad Taghi Kardi, Vahid Shaygannejad

PII: S2211-0348(18)30276-1

DOI: https://doi.org/10.1016/j.msard.2018.08.009

Reference: MSARD 932

To appear in: Multiple Sclerosis and Related Disorders

Received date: 24 September 2017

Revised date: 20 July 2018 Accepted date: 9 August 2018



Please cite this article as: Bahram Bagherpour, Mansour Salehi, Rasool Jafari, Akram Bagheri, Ali Kiani, Masoud Edalati, Mohammad Taghi Kardi, Vahid Shaygannejad, Promising effect of rapamycin on multiple sclerosis, *Multiple Sclerosis and Related Disorders* (2018), doi: https://doi.org/10.1016/j.msard.2018.08.009

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Highlights

The effect of rapamycin, as an immunosuppressive agent, was evaluated on the patients with relapsing-remitting multiple sclerosis and the results showed promising points which are as follows:

- Patients' had some degrees of significant reduction in mean plaque area size
- The expression rate of FOXP3 and GARP genes in regulatory T cells increased after the therapy which could favor the treatment of MS.
- Its side effects are negligible and as tested it showed to be a safe treatment
- It decreased patients' expanded disability status scale (EDSS) in some cases

Download English Version:

https://daneshyari.com/en/article/10212454

Download Persian Version:

https://daneshyari.com/article/10212454

<u>Daneshyari.com</u>